Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"

Haematologica. 2015 Mar;100(3):e120-1. doi: 10.3324/haematol.2014.123232.
No abstract available

Keywords: chronic myeloid leukemia; radotinib.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm*
  • Female
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Humans
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Male
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl